Income Statement
KALVISTA PHARMACEUTICALS, INC.
KALV
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Apr 30, 2025 2025 FY | Apr 30, 2024 2024 FY | Apr 30, 2023 2023 FY | Apr 30, 2022 2022 FY | Apr 30, 2021 2021 FY | Apr 30, 2020 2020 FY | Apr 30, 2019 2019 FY | Apr 30, 2018 2018 FY | Apr 30, 2017 2017 FY | Dec 31, 2015 2015 FY |
|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - | 12.69 | 16.13 | 8.39 | - | - |
|
Cost of Revenue
|
- | - | - | - | - | - | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - | 12.69 | 16.13 | 8.39 | - | - |
|
Operating Expenses
|
188.00 | 140.45 | 110.87 | 96.61 | 57.92 | 53.22 | 45.95 | 27.10 | 23.84 | 21.07 |
|
Research & Development
|
71.71 | 86.17 | 80.28 | 70.17 | 41.29 | 40.19 | 35.02 | 18.24 | 12.67 | 16.20 |
|
Selling, General & Administrative
|
116.29 | 54.28 | 30.60 | 26.45 | 16.64 | 13.03 | 10.93 | 8.86 | 11.18 | 4.87 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - | - | - |
|
Operating Income
|
-188.00 | -140.45 | -110.87 | -96.61 | -57.92 | -40.53 | -29.82 | -18.71 | -23.84 | -21.07 |
|
Non-Operating Income
|
7.94 | 13.80 | 17.96 | 14.27 | 11.68 | 11.29 | 9.13 | 2.90 | 3.74 | -3.81 |
|
Interest Income
|
6.44 | 3.90 | 2.23 | 1.09 | 0.90 | 1.83 | 1.40 | 0.08 | 0.04 | 0.01 |
|
Interest Expense
|
- | - | - | - | - | - | - | - | - | 1.19 |
|
Other Non-Op Income / Expense
|
4.81 | 9.77 | 15.64 | 14.72 | 9.93 | 9.83 | 7.68 | 6.80 | 2.33 | 0.55 |
|
Income Before Tax
|
-180.05 | -126.64 | -92.91 | -82.34 | -46.24 | -29.24 | -20.69 | -15.81 | - | - |
|
Income Tax Expense
|
3.39 | 0.00 | 0.00 | 0.00 | 0.00 | -0.12 | 0.12 | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - | - | - | - | - | - |
|
Net Income
|
-183.44 | -126.64 | -92.91 | -82.34 | -46.24 | -29.12 | -20.82 | -15.81 | -18.60 | -24.85 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Apr 30, 2025 2025 FY | Apr 30, 2024 2024 FY | Apr 30, 2023 2023 FY | Apr 30, 2022 2022 FY | Apr 30, 2021 2021 FY | Apr 30, 2020 2020 FY | Apr 30, 2019 2019 FY | Apr 30, 2018 2018 FY | Apr 30, 2017 2017 FY | Dec 31, 2015 2015 FY |
|---|---|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
-187.05 | -139.63 | -110.15 | -96.01 | -57.39 | -40.02 | -29.44 | -18.53 | -23.84 | -20.93 |
|
Earnings Per Share (Basic)
|
-3.69 | -3.44 | -3.33 | -3.36 | - | - | - | - | - | - |
|
Diluted EPS
|
-3.69 | -3.44 | -3.33 | -3.36 | - | - | - | - | - | - |
|
Weighted Average Shares
|
49.65 | 36.79 | 27.89 | 24.47 | - | - | - | - | - | - |
|
Diluted Weighted Avg Shares
|
49.65 | 36.79 | 27.89 | 24.47 | - | - | - | - | - | - |
|
Comprehensive Income
|
-185.17 | -127.07 | -92.11 | -84.77 | -45.79 | -29.07 | -21.63 | -14.27 | -21.17 | - |